Skip to main content
Top
Published in: Journal of Gastroenterology 8/2019

01-08-2019 | Helicobacter Pylori | Original Article—Alimentary Tract

A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report

Authors: Toshihiko Kakiuchi, Muneaki Matsuo, Hiroyoshi Endo, Aiko Nakayama, Keiko Sato, Ayako Takamori, Kazumi Sasaki, Mitsuhiro Takasaki, Megumi Hara, Yasuhisa Sakata, Masumi Okuda, Shogo Kikuchi, Yuichiro Eguchi, Hirokazu Takahashi, Keizo Anzai, Kazuma Fujimoto

Published in: Journal of Gastroenterology | Issue 8/2019

Login to get access

Abstract

Background

To present the strategies and preliminary findings of the first 3 years after implementing a Helicobacter pylori screening and eradication program to prevent gastric cancer in Saga Prefecture.

Methods

A screening and treatment program to eradicate H. pylori from third-grade junior high students was started in Saga Prefecture in 2016, using local governmental grants. Screening was with urinary anti-H. pylori antibody tests, followed by H. pylori stool antigen tests for students who were antibody positive. Those positive on both tests underwent H. pylori eradication by triple therapy based on a potassium-competitive acid blocker.

Results

From 2016 to 2018, the participation rate was 83.1% and the H. pylori infection rate was 3.1% (660/21,042). The participation rates were higher in 2017 (85.4%) and 2018 (85.9%) compared with 2016 (78.5%) (P < 0.0001), and the infection rate also decreased in a time-dependent manner (2016: 3.6%, 2017: 3.3%, 2018: 2.5%, P = 0.0001). In total, 501 students positive for H. pylori received eradication therapy (85.1% success) and adverse events occurred in 20 of these (4.0%). However, no serious complications occurred.

Conclusions

The H. pylori screening and eradication project for school students in Saga Prefecture has started successfully and we have seen both a steady increase in the participation rate and a steady decrease in the infection rate, without major safety concerns.
Literature
1.
go back to reference Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed
2.
go back to reference Park JY, Forman D, Waskit LA, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins. 2018;10:e163.CrossRefPubMed Park JY, Forman D, Waskit LA, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins. 2018;10:e163.CrossRefPubMed
3.
go back to reference Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354–61.CrossRefPubMed Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354–61.CrossRefPubMed
4.
go back to reference Hatakeyama H. Helicobacter pylori CagA and cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:306–16.CrossRefPubMed Hatakeyama H. Helicobacter pylori CagA and cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:306–16.CrossRefPubMed
5.
go back to reference Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Jpn J Cancer Res. 2000;91:774–9.CrossRefPubMedPubMedCentral Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Jpn J Cancer Res. 2000;91:774–9.CrossRefPubMedPubMedCentral
6.
go back to reference Ekstom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784–91.CrossRef Ekstom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784–91.CrossRef
7.
go back to reference Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.CrossRefPubMed Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.CrossRefPubMed
8.
go back to reference Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22:e12415.CrossRefPubMedCentral Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22:e12415.CrossRefPubMedCentral
10.
go back to reference Asaka M, Mabe K, Matsushima R, et al. Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin N Am. 2015;44:639–48.CrossRef Asaka M, Mabe K, Matsushima R, et al. Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin N Am. 2015;44:639–48.CrossRef
11.
go back to reference Tsutsumi K, Kusano C, Suzuki S, et al. Diagnostic accuracy of latex agglutination turbidimetric immunoassay in screening adolescents for Helicobacter pylori infection in Japan. Digestion. 2018;98:75–80.CrossRefPubMed Tsutsumi K, Kusano C, Suzuki S, et al. Diagnostic accuracy of latex agglutination turbidimetric immunoassay in screening adolescents for Helicobacter pylori infection in Japan. Digestion. 2018;98:75–80.CrossRefPubMed
12.
go back to reference Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42:21–7.CrossRefPubMed Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42:21–7.CrossRefPubMed
13.
go back to reference Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMed Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMed
15.
go back to reference Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter. 2008;13:278–81.CrossRefPubMed Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter. 2008;13:278–81.CrossRefPubMed
16.
go back to reference Nozaki K, Shimizu N, Ikehara Y, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–9.CrossRefPubMed Nozaki K, Shimizu N, Ikehara Y, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–9.CrossRefPubMed
17.
go back to reference Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92–105.CrossRefPubMed Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92–105.CrossRefPubMed
18.
go back to reference Akamatsu T, Ichikawa S, Okada S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353–60.CrossRefPubMed Akamatsu T, Ichikawa S, Okada S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353–60.CrossRefPubMed
19.
go back to reference Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:S16–9.CrossRef Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:S16–9.CrossRef
20.
go back to reference Okuda M, Kamiya S, Booka M, et al. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antigen in children. Pediatr Int. 2013;55:337–41.CrossRefPubMed Okuda M, Kamiya S, Booka M, et al. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antigen in children. Pediatr Int. 2013;55:337–41.CrossRefPubMed
21.
go back to reference Yamamoto T, Ishii T, Kawakami T, et al. Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis. World J Gastroenterol. 2005;11:412–4.CrossRefPubMedPubMedCentral Yamamoto T, Ishii T, Kawakami T, et al. Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis. World J Gastroenterol. 2005;11:412–4.CrossRefPubMedPubMedCentral
22.
go back to reference Tamamura T, Morita E, Kondo T, et al. Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008–2010. Nagoya J Med Sci. 2012;74:63–70. Tamamura T, Morita E, Kondo T, et al. Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008–2010. Nagoya J Med Sci. 2012;74:63–70.
23.
go back to reference Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:818–91. Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:818–91.
24.
go back to reference Fukuda Y, Tomita T, Hori K, et al. Evaluation of a novel Helicobacter pylori stool antigen detection kit, Testmate rapid pylori antigen, for rapid diagnosis of Helicobacter pylori infection. Jpn J Med Pharm Sci. 2004;52:469–74. Fukuda Y, Tomita T, Hori K, et al. Evaluation of a novel Helicobacter pylori stool antigen detection kit, Testmate rapid pylori antigen, for rapid diagnosis of Helicobacter pylori infection. Jpn J Med Pharm Sci. 2004;52:469–74.
25.
go back to reference Zebala Torrres B, Luceno Y, Lagomarcino AJ, et al. Review: prevalence and dynamics of Helicobacter pylori infection during childhood. Helicobacter. 2017;22:e12399.CrossRef Zebala Torrres B, Luceno Y, Lagomarcino AJ, et al. Review: prevalence and dynamics of Helicobacter pylori infection during childhood. Helicobacter. 2017;22:e12399.CrossRef
26.
go back to reference Tanaka Y, Sakata Y, Hara M, et al. Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers. Intern Med. 2017;56:2979–83.CrossRefPubMedPubMedCentral Tanaka Y, Sakata Y, Hara M, et al. Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers. Intern Med. 2017;56:2979–83.CrossRefPubMedPubMedCentral
27.
go back to reference Takeshita E, Sakata Y, Hara M, et al. Higher frequency of reflux symptoms and acid-related dyspepsia in females than males regardless of endoscopic esophagitis: cross sectional analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion. 2016;93:266–71.CrossRefPubMed Takeshita E, Sakata Y, Hara M, et al. Higher frequency of reflux symptoms and acid-related dyspepsia in females than males regardless of endoscopic esophagitis: cross sectional analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion. 2016;93:266–71.CrossRefPubMed
28.
go back to reference Fujimoto Y, Furusyo N, Toyoda K, et al. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter. 2007;12:170–6.CrossRefPubMed Fujimoto Y, Furusyo N, Toyoda K, et al. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter. 2007;12:170–6.CrossRefPubMed
29.
go back to reference Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.CrossRefPubMed Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.CrossRefPubMed
30.
go back to reference Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2014;20:133–8.CrossRefPubMed Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2014;20:133–8.CrossRefPubMed
32.
go back to reference Rogers AH. The source of infection in the intrafamilial transfer of Streptococcus mutans. Caries Res. 1981;15:26–31.CrossRefPubMed Rogers AH. The source of infection in the intrafamilial transfer of Streptococcus mutans. Caries Res. 1981;15:26–31.CrossRefPubMed
33.
34.
go back to reference Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65:1439–46.CrossRefPubMedPubMedCentral Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65:1439–46.CrossRefPubMedPubMedCentral
35.
go back to reference Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Dig Dis Sci. 2017;62:3069–76.CrossRefPubMed Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Dig Dis Sci. 2017;62:3069–76.CrossRefPubMed
36.
go back to reference Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2018;4:1–7. Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2018;4:1–7.
37.
go back to reference Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97:212–8.CrossRefPubMed Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97:212–8.CrossRefPubMed
38.
go back to reference Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–56.CrossRefPubMed Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–56.CrossRefPubMed
39.
go back to reference Khurana R, Fischbach L, Chiba N, et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:423–36.CrossRef Khurana R, Fischbach L, Chiba N, et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:423–36.CrossRef
40.
go back to reference Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guideline for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;23:2453–8. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guideline for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;23:2453–8.
41.
go back to reference Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22:e12383.CrossRef Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22:e12383.CrossRef
42.
go back to reference Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838–43.CrossRefPubMed Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838–43.CrossRefPubMed
43.
go back to reference Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:18–90.CrossRef Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:18–90.CrossRef
44.
go back to reference Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;55:1372–82.CrossRef Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;55:1372–82.CrossRef
45.
go back to reference Montes M, Villalon FN, Eizaguirre FJ, et al. Helicobacter pylori infection in children. Antimicrobial resistance and treatment response. Helicobacter. 2015;20:169–75.CrossRefPubMed Montes M, Villalon FN, Eizaguirre FJ, et al. Helicobacter pylori infection in children. Antimicrobial resistance and treatment response. Helicobacter. 2015;20:169–75.CrossRefPubMed
46.
go back to reference Ogata SK, Godoy AP, da Silva Patricio FR, et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645–8.CrossRefPubMed Ogata SK, Godoy AP, da Silva Patricio FR, et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645–8.CrossRefPubMed
47.
go back to reference Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214–20.CrossRefPubMed Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214–20.CrossRefPubMed
48.
go back to reference Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57–61.CrossRefPubMed Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57–61.CrossRefPubMed
49.
go back to reference Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538–43.CrossRefPubMed Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538–43.CrossRefPubMed
50.
go back to reference Adachi T, Matsui S, Watanabe T, et al. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first-line eradication for Helicobacter pylori. Oncology. 2017;93:15–9.CrossRefPubMed Adachi T, Matsui S, Watanabe T, et al. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first-line eradication for Helicobacter pylori. Oncology. 2017;93:15–9.CrossRefPubMed
51.
go back to reference Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53:718–24.CrossRefPubMed Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53:718–24.CrossRefPubMed
52.
go back to reference Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25–40.CrossRefPubMed Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25–40.CrossRefPubMed
Metadata
Title
A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report
Authors
Toshihiko Kakiuchi
Muneaki Matsuo
Hiroyoshi Endo
Aiko Nakayama
Keiko Sato
Ayako Takamori
Kazumi Sasaki
Mitsuhiro Takasaki
Megumi Hara
Yasuhisa Sakata
Masumi Okuda
Shogo Kikuchi
Yuichiro Eguchi
Hirokazu Takahashi
Keizo Anzai
Kazuma Fujimoto
Publication date
01-08-2019
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2019
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01559-9

Other articles of this Issue 8/2019

Journal of Gastroenterology 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.